TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Immunization
Vaxfectin(R)-formulated Measles DNA Vaccine Could Address Unmet Need for Infants
September 2nd, 2008
Vical Incorporated (NASDAQ:VICL) announced that results from nonhuman primate studies of a Vaxfectin(R)-formulated DNA vaccine for measles, published in the August issue of Clinical and Vaccine Immunology(1), offer a promising approach to the development of a measles vaccine to address an unmet need for human infants. Vical recently reported breakthrough preliminary Phase 1 trial results for the company's H5N1 pandemic influenza DNA vaccines formulated with the same Vaxfectin(R) adjuvant. In the article, authors from the Johns Hopkins Bloomberg School of Public Health, the Johns Hopkins School of Medicine, and Vical detailed results from studies in juvenile and infant...
Source: TB & Outbreaks Week (2008-09-02)
|
